MMWR

RSV immunization coverage remains low despite new options for infant protection

August 26, 2025

Only 29% of U.S. infants born October 2023–March 2024 received protection against respiratory syncytial virus (RSV) through either nirsevimab monoclonal antibody or maternal vaccination, according to CDC data from 33 states and D.C. Coverage varied widely by state, ranging from 11% in Nevada to 53% in Vermont. Among infants who received nirsevimab, only 38% received it within the first week of life, considered the optimal window for protection. Despite low uptake, nirsevimab demonstrated strong effectiveness in reducing RSV-related hospitalizations by 90% in a separate CDC analysis. These findings underscore the need for improved provider education, streamlined access, and timely postpartum administration to maximize protection during the vulnerable early months of life.

Source:

Boundy EO, et al. (2025, August 21). MMWR Morb Mortal Wkly Rep. Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination - United States, October 2023-March 2024. https://pubmed.ncbi.nlm.nih.gov/40839535/